Compare AMPH & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPH | URGN |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.8M | 1.4B |
| IPO Year | 2005 | 2016 |
| Metric | AMPH | URGN |
|---|---|---|
| Price | $18.72 | $27.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $28.38 | ★ $29.29 |
| AVG Volume (30 Days) | 710.6K | ★ 816.1K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $719,887,000.00 | $1,128,000.00 |
| Revenue This Year | $6.90 | $129.09 |
| Revenue Next Year | $4.64 | $70.96 |
| P/E Ratio | $137.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.65 | $4.36 |
| 52 Week High | $31.26 | $32.37 |
| Indicator | AMPH | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 54.22 |
| Support Level | $16.84 | $27.34 |
| Resistance Level | $20.08 | $30.00 |
| Average True Range (ATR) | 0.80 | 1.64 |
| MACD | 0.11 | -0.34 |
| Stochastic Oscillator | 73.53 | 14.12 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.